Actionable insights straight to your inbox

Equities logo

MacroGenics Signs $586 Million Licensing Deal With Synaffix for Antibody-Drug Conjugate Technology

The appetite for next generation breast cancer therapies continues to grow unabated.
The biotech sector has been taking a beating during the volatility this week as investors sell-off assets for fear of compounding the risk factors of the choppy market and the characteristically